All In Biotech

Drug Trial Radar · NCT05206370

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 792 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

792

Actual

Start

Jan 20, 2022

Primary completion

Mar 21, 2023

Study completion Mar 21, 2023

Sponsor

Lead sponsor
Achieve Life SciencesIndustry
Sponsor type
Industry
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.

Conditions

  • Smoking Cessation

Interventions

  • CytisiniclineDrug

    film-coated oral tablets containing 3 mg cytisinicline

  • PlaceboDrug

    film-coated oral tablets containing matched placebo

  • Behavioral supportBehavioral

    Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6Time frame: Weeks 3 to 6
  2. Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12Time frame: Weeks 9 to 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Accel Research Sites - DeLand Clinical Research Unit

    DeLand, Florida

  • Alliance for Multispecialty Research, LLC

    Fort Myers, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Affinity Health Corp

    Oak Brook, Illinois

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana

  • Global Medical Institutes LLC; Princeton Medical Institute

    Princeton, New Jersey

  • Trial Management Associates, LLC

    Wilmington, North Carolina

  • Velocity Clinical Research, Inc.

    Cleveland, Ohio

  • Aventiv Research Inc

    Columbus, Ohio

  • Intend Research

    Norman, Oklahoma

  • Clinical Research Associates, Inc.

    Nashville, Tennessee

  • Health Research of Hampton Toads, Inc

    Newport News, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.